Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01838317 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01838317 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT01838317, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and insulin metabolism). In addition the investigators want to determine whether or not treatment with pioglitazone results in (1) improvement in the size of the tumor, (2) weight gain, (3) improved ability to function during the day and (4) quality of life.
Interventions
- DRUG Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01838317
The ClinicalTrials.gov registry entry for NCT01838317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pioglitazone is the first listed.
NCT01838317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01838317 about?
NCT01838317 is a clinical study titled "A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas". This study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and insulin metabolism). In addition the investigators want to determine whethe...
What is the current status of trial NCT01838317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2013-05. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT01838317?
The interventions under investigation include: Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT01838317?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.